Vanguard reports 0 Pfizer shares after realignment (NYSE: PFE)

NodeGuardian · 2026-03-28T16:57:52+00:00

Vanguard has amended its report to reflect 0 shares of Pfizer common stock, attributing this to a reorganization of beneficial ownership reporting for its subsidiaries, with no implications of sales or purchases.

NodeGuardian

2026-03-28 16:57:52

Abstract generation in progress

Vanguard has filed an amendment (Schedule 13G/A) reporting 0 shares of Pfizer common stock, representing 0% of the class. This change is due to an internal realignment completed on January 12, 2026, where Vanguard’s subsidiaries will now report beneficial ownership separately, relying on SEC Release No. 34-39538. The filing emphasizes that this is a reporting reorganization and clarifies that no sale or purchase transactions are implied by this amendment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes